Best Peptides for Cognitive Function: A Research Comparison

Peptide research on cognitive function draws on a small but distinctive compound set. The unifying downstream signal across most of the class is BDNF (brain-derived neurotrophic factor), the most-studied neurotrophic factor in adult synaptic plasticity, depression, and neurodegeneration research. Colucci-D’Amato and colleagues’ 2020 IJMS review on BDNF is the best single-source framing for the research landscape ¹.

The four compounds compared here: Semax (an ACTH(4-10) analogue with strong BDNF-elevation data), Selank (a tuftsin analogue bridging anxiolytic and cognitive endpoints), Cerebrolysin (a porcine-brain-derived peptide preparation with Phase 3 stroke-recovery data), and DSIP (included for sleep-quality adjunct use in longer cognitive protocols). Honest framing: Cerebrolysin has the strongest clinical evidence base, Semax has the cleanest mechanism data, and Selank sits at the anxiety-cognition intersection.

Comparison at a glance

How to choose between them

Three questions drive the choice.

Is the research targeting BDNF specifically? Semax is the cleanest tool. Dolotov and colleagues’ 2006 Dokl Biol Sci paper established BDNF elevation in basal forebrain after Semax administration ², and subsequent research has replicated this across brain regions. For a protocol that measures BDNF as a primary endpoint, Semax is the reference compound.

Does the research design involve stress, anxiety, or mood as covariates of cognition? Selank is the compound. Its modulation of GABAergic and enkephalinergic systems produces anxiolytic effects without sedation, and its cognitive endpoints are often studied alongside stress-response endpoints. Kolomin and colleagues’ transcriptomic work on Selank is the definitive Russian-programme reference ³.

Does the research need the strongest available clinical base? Cerebrolysin is the answer, by a wide margin. Muresanu and colleagues’ CARS trial (Cerebrolysin and Recovery After Stroke) is a Phase 3 registered-drug trial programme ⁴, not preclinical or limited open-label work. Trade-off: the compound is a standardised mixture rather than a single peptide, which reduces its usefulness for mechanism-specific pharmacology research.

Is chronic sleep disruption confounding the cognitive endpoints? DSIP as an adjunct. Kovalzon’s 2006 J Neurochem review remains the most-cited (though honestly-qualified) reference on its sleep-architecture effects ⁵. Researchers use it as a sleep-quality stabiliser in longer cognitive protocols rather than as a primary cognitive compound.

Semax

Semax is a synthetic heptapeptide analogue of the ACTH(4-10) fragment, with a C-terminal Pro-Gly-Pro extension that confers proteolytic stability and extends central-nervous-system exposure beyond peripheral plasma clearance. Mechanism is well-characterised in preclinical work: elevation of hippocampal and basal-forebrain BDNF, NGF modulation, and effects on monoaminergic (dopaminergic, serotonergic) tone. Russian clinical registration exists for ischaemic-stroke recovery.

Where the literature stands: Dolotov and colleagues’ 2006 Dokl Biol Sci paper is the foundational BDNF reference ². Subsequent work has confirmed the BDNF effect across dose ranges and brain regions. Western clinical replication is limited; most of the supportive data is from the Russian research programme.

Why a researcher picks Semax: BDNF-specific research, neurotrophic-factor pharmacology, or cognition research where a well-characterised mechanism is more important than the breadth of clinical trial data. Intranasal dosing 2–3 times daily is the standard route; direct nose-to-brain delivery bypasses peripheral-plasma half-life concerns.

Selank

Selank is a synthetic heptapeptide analogue of the natural tetrapeptide tuftsin. Its research profile sits at the overlap of anxiolysis and cognition. Mechanism involves modulation of GABAergic and enkephalinergic systems and elevation of BDNF expression in hippocampus (distinct from Semax’s primarily basal-forebrain BDNF effect). Russian clinical registration exists for generalised anxiety indications.

Where the literature stands: Kolomin and colleagues’ transcriptomic profiling of Selank in rat hippocampus and spleen ³ is representative of the mechanistic research. The anxiolytic efficacy is supported in smaller Russian clinical studies; Western replication is limited.

Why a researcher picks Selank: stress-cognition research, anxiety-cognition overlap protocols, or cognitive work where the research context involves patients or animals under sustained stress. Intranasal dosing; 14-day on / 14-day off cycling is common to mirror Russian clinical protocols.

Cerebrolysin

Cerebrolysin is categorically different from the other three. It is a standardised enzymatically-produced mixture of porcine-brain-derived low-molecular-weight peptides and free amino acids. The mixture approximates neurotrophic-factor (BDNF, NGF, GDNF) signalling in preclinical models, and the compound has been registered in the EU, Russia, China, and most of Asia for stroke and dementia indications.

Where the literature stands: the CARS trial (Muresanu and colleagues, 2016 Stroke) is one of several Phase 3 registered-drug trials ⁴. Additional clinical evidence covers vascular dementia, traumatic brain injury, and acute ischaemic stroke across multiple decades.

Why a researcher picks Cerebrolysin: research questions where the strongest possible clinical evidence base matters more than single-peptide mechanism clarity. Route is either IM or slow IV infusion; the compound is supplied in pre-filled ampoules, not lyophilised powder. Typical regimen is daily administration for 10–20 days, 2 times per year.

DSIP

DSIP is included in this article not because it is a nootropic compound per se, but because sleep quality is a major cognitive-research confounder. Its mechanism is incompletely characterised (see the sleep and recovery article for the fuller treatment), and the evidence base is thinner than for the other three compounds here.

Where the literature stands: Kovalzon and Strekalova’s 2006 J Neurochem review is the clearest contemporary summary, and its “still unresolved riddle” framing is accurate ⁵.

Why a researcher picks DSIP in a cognitive protocol: sleep-quality adjunct in longer cognitive research where chronic sleep disruption would confound outcomes. Not a primary cognitive tool.

Stacking considerations

• Semax + Selank is the most common cognitive-research pairing. Both are intranasal, both hit BDNF through different mechanisms (Semax primarily basal forebrain, Selank primarily hippocampal), and the anxiolytic effect of Selank complements the cognitive effect of Semax. Protocols often alternate 14-day on periods rather than running both continuously.
• Cerebrolysin alone is the standard for stroke-recovery research; it is rarely stacked with the other compounds because the trial evidence supports monotherapy.
• DSIP + Semax is used in longer-duration cognitive research where sleep stabilisation is an adjunct to the primary BDNF research question.

Where to order

All four compounds are supplied by Thailand Peptides from the Bangkok research desk. Same-week Thailand delivery, lab reports on request, WhatsApp ordering.

• Buy Semax: intranasal research solution, ≥98% HPLC purity
• Buy Selank: intranasal research solution, ≥98% HPLC purity
• Buy Cerebrolysin: pre-filled ampoules, research-grade
• Buy DSIP: 5 mg vials, ≥98% HPLC purity

Semax + Selank is the most-ordered pairing in this category. Cerebrolysin ordering involves different logistics because it ships as liquid ampoules rather than lyophilised powder; confirm shipping route in chat.